Scott Oh, DO
Pulmonary Disease · Los Angeles, CANPI 1164507331
Payments from drug & device makers
Across 358 payments — averaging $702.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$232K
- Boston Scientific$12K
- Pulmonx Corporation$4K
- Pinnacle Biologics, Inc$2K
- Covidien LP$460
- Medtronic$435
- plus $1K from 7 others
What the payments were for
- Consulting fees$8,0753%
- Speaking & faculty fees$150,55060%
- Travel & lodging$15,3906%
- Food & beverage$16,1956%
- Education$61,30024%
- Gifts$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 283 | $231,952 |
| Boston Scientific | 26 | $11,803 |
| Pulmonx Corporation | 19 | $4,117 |
| Pinnacle Biologics, Inc | 8 | $1,685 |
| Covidien LP | 5 | $460 |
| Medtronic | 4 | $435 |
| Johnson & Johnson | 4 | $418 |
| Siemens Medical Solutions USA, Inc. | 3 | $308 |
| Boehringer Ingelheim | 1 | $135 |
| Bard Access Systems, Inc. | 1 | $90 |
| Auris Health, Inc. | 2 | $87 |
| Fujifilm Healthcare Americas Corporation | 1 | $35 |
| Ambu Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$167,223
- DA VINCI SP$60,450
- GENERAL PULMONARY$5,584
- ACQUIRE$4,094
- CHARTIS CATHETER$3,401
- ZEPHYR ENDOBRONCHIAL VALVE$3,401
- ZEPHYR DELIVERY CATHETER$3,401
- PULMONX CHARTIS TABLET CONSOLE$3,401
- Photofrin$1,530
- COREDX$1,050
- ION$600
- superDimension$547
- Pulmonx Endobronchial Valve EBV$436
- Monarch Platform$407
- GENERAL - THERAPIES$393
- ILLUMISITE$312
- OFEV$135
- Cios Spin$128
- EXPECT$114
- EXALT BX 2$108
How this compares
$251,532 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,149 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,310 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $483 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.